SEARCH

SEARCH BY CITATION

References

  • 1
    Goeree R, Burke N, O'Reilly D, et al. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Review. Curr Med Res Opin 2007;23:67182.
  • 2
    Sculpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in health care: a review and case studies. Health Technol Assess 2004;49:1192.
  • 3
    Welte R, Feenstra T, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004;22:85776.
  • 4
    Boulenger S, Nixon J, Drummond M, et al. Can economic evaluations be made more transferable? Eur J Health Econ 2005;6:33446.
  • 5
    Urdahl H, Manca A, Sculpher M. Assessing generalisability in model-based economic evaluation studies. A structured review in osteoporosis. Pharmacoeconomics 2006;24:118197.
  • 6
    Wardley AM, Cameron DA, Bell R, et al. Cost–effectiveness analysis of adjuvant therapy with trastuzumab (Herceptin) for early breast cancer. Ann Oncol 2006;17:ix95.
  • 7
    Nice Appraisal guidance 107. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. August 2006.
  • 8
    Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583637.
  • 9
    Health Insurance Council. Fair and Sustainable Care. Amstelveen, 2006 (in Dutch).
  • 10
    Hayman JA, Hillner BE, Harris JR, Weeks JC. Cost–effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. J Clin Oncol 1998;16:10229.
  • 11
    Carter KJ, Ritchey NP, Castro F, et al. Treatment of early-stage breast cancer in the elderly: a health–outcome-based approach. Med Decis Making 1998;18:2139.
  • 12
    Van Hanswijck de Jonge P, Doyle S, Farina C, Walker M. Poster Presentation 190 P: Elicitation of UK Health utilities in primary, recurrent and metastatic breast cancer. 31st European Society Medical Oncology (ESMO), Istanbul, Turkey, 2006.
  • 13
    Lidgren M, Wilking N, Jonsson B, Rehnberg C. Health related quality of life in different states of breast cancer. Qual Life Res 2007107381.
  • 14
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:165972.
  • 15
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687717.
  • 16
    Koopmanschap MA, Rutten FF, Van Ineveld BM, Van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:17189.